Feasibility of primer shot radiotherapy for non-small cell lung cancer (PRIMER)

• Conditions: Non-small cell lung cancer; non-small-cell lung cancer; 10027656

• Registration Number: NL-OMON56897
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 35

Inclusion Criteria

• Age >= 18 years
• NSCLC (either pathology proven or sufficient clinical suspicion to be treated
as NSCLC), referred for palliative radiotherapy of at least the primary tumor
site (to eleviate or prevent symptoms like shortness of breath, coughing, pain
or hemoptysis).
• NSCLC, stage 2-4
• WHO performance score 0*2.
• Provision of signed, written and dated IC prior to any study specific
procedures.

Exclusion Criteria

• Interstitial lung disease
• Treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors
• Prior thoracic radiotherapy (>20 Gy EQD2 a/b 3) overlapping with the current
planning target volume
• Pregnant

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study endpoint is whether patients finish the radiotherapy schedule as<br /><br>planned (completion of all 5 fractions and two or less additional unplanned<br /><br>days between fractions).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p> Secondary endpoints are tumor response at the end of treatment and 3 months<br /><br>thereafter, and acute toxicity.</p><br>